Clinical trials: Multiple Sclerosis Relapse
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Relapse Remitting Multiple Sclerosis
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting…
- Trial name
- NCT02038049
- Testing
- VAY736
- Where
- 5 sites in United States, Czechia and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis Relapse
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
The primary objective was to demonstrate the effect of teriflunomide, in comparison to placebo, on frequency of Multiple Sclerosis (MS) relapses in patients with relapsing forms of MS who are treated with Interferon-beta…
- Trial name
- TERACLES (NCT01252355)
- Testing
- Teriflunomide, Interferon-beta (IFN-beta)
- Where
- 185 sites in United States, Argentina and 26 more
- Volunteers
- 534 people
- Sponsor
- Sanofi